FDA/CDC

FDA: Recall of select EpiPen products

Publish date: April 1, 2017
By
Lucas Franki

 

Meridian Medical Technologies has issued a voluntary recall for 13 lots of EpiPen products, according to a press release from the U.S. Food and Drug Administration.

The voluntary recall includes EpiPen and EpiPen Jr. Auto-Injector distributed between Dec. 17, 2015, and July 1, 2016 by Mylan Specialty. Products included in the recall may contain a defective part which would prevent the device from activating.

“While the number of reported failures is small, EpiPen products that potentially contain a defective part are being recalled because of the potential for life-threatening risk if a severe allergic reaction goes untreated,” the FDA said in the press release.

Consumers who need their EpiPens should keep them until a they obtain a replacement, the FDA recommended.

Find the full press release on the FDA website.

Recommended Reading

Antibiotics overprescribed during asthma-related hospitalizations
MDedge Internal Medicine
Mylan’s generic EpiPen – a price break or marketing maneuver?
MDedge Internal Medicine
LABA withdrawal does not worsen asthma control
MDedge Internal Medicine
Benralizumab reduces exacerbations in pivotal severe asthma trials
MDedge Internal Medicine
ACOS definitions under fire
MDedge Internal Medicine
EpiPen cost increases far exceed overall medical inflation
MDedge Internal Medicine
Lanadelumab reduced hereditary angioedema attacks by 88%-100%
MDedge Internal Medicine
Uptick found in severe allergy shot reactions
MDedge Internal Medicine
Survey finds chronic rhinosinusitis common, burdensome
MDedge Internal Medicine
Oral agent found promising for subset of chronic rhinosinusitis patients
MDedge Internal Medicine

Related Articles